Cstone Pharmaceuticals To Present Cancer Results at 2024 ASCO
Cstone Pharmaceuticals (HKG:2616) announced that the company will present Phase I results for its new cancer drug at the 2024 American Society of Clinical Oncology (ASCO) Meeting in a poster session,
Cstone Pharmaceuticals' CEO Boosts Stakeholding
Cstone Pharmaceuticals' (HKG:2616) CEO Jianxin Yang bought around an additional 3.3 million shares on the market during the six months ended today, Monday, a same-day filing on the Hong Kong bourse sa
Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5%
Cstone Pharmaceuticals (HKG:2616) reported a loss for the year attributable to owners of about 367.2 million yuan, down from a loss of 902.7 yuan in the previous year, according to the annual results
China Accepts CStone Pharmaceuticals' Manufacturing Application for RET Inhibitor
China's medical products administrator accepted CStone Pharmaceuticals' (HKG:2616) manufacturing localization application for its pralsetinib RET inhibitor, according to a Tuesday filing with the Hong
Cstone Pharmaceuticals Cancer Drug Gets Supplemental Biologics License Application Approved
Cstone Pharmaceuticals (HKG:2616) said China's National Medical Products Administration (NMPA) approved a supplemental biologics license application (sBLA) for sugemalimab in combination with fluoropy
CStone Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer
Insider Purchases Worth CN¥6.54m See Losses As CStone Pharmaceuticals Market Value Drops To HK$1.4b
The recent price decline of 31% in CStone Pharmaceuticals' (HKG:2616) stock may have disappointed insiders who bought CN¥6.54m worth of shares at an average price of CN¥2.52 in the past 12 months. In
CStone Pharmaceuticals Removed From Hong Kong Stock Connect; Shares Plunge 26%
CStone Pharmaceuticals (HKG:2616) has been removed from the Hong Kong Stock Connect effective March 4, a Monday filing said. The removal from the Stock Connect program comes after the company was deli
CStone Pharmaceuticals Arm to Sell Ivosidenib Business for $50 Million
CStone Pharmaceuticals (HKG:2616) arm CStone Pharmaceuticals (Suzhou) has agreed to sell its CStone Ivosidenib business to France-based pharma group Les Laboratoires Servier for $50 million. CStone an
Insider Buyers At CStone Pharmaceuticals Likely Disappointed With 16% Slide
Insiders who bought CN¥6.54m worth of CStone Pharmaceuticals' (HKG:2616) stock at an average buy price of CN¥2.52 over the last year may be disappointed by the recent 16% decrease in the stock. This
CStone Pharmaceuticals' H1 Loss Narrows
CStone Pharmaceuticals' (HKG:2616) loss narrowed to 210.1 million yuan, or 0.17 yuan per share, in the first half, from 361.6 million yuan, or 0.31 yuan per share, in the year-ago period, a Tuesday fi
Insider Buyers At CStone Pharmaceuticals Likely Disappointed With 15% Slide
The recent price decline of 15% in CStone Pharmaceuticals' (HKG:2616) stock may have disappointed insiders who bought CN¥14m worth of shares at an average price of CN¥3.45 in the past 12 months. This
China Approves CStone Pharmaceuticals' New Drug Application for Lung Cancer Treatment; Shares Rise 3%
China's medical products administrator approved CStone Pharmaceuticals' (HKG:2616) supplemental new drug application for its Gavreto treatment for non-small cell lung cancer, a Tuesday filing said. Th
CStone Pharmaceuticals CEO Boosts Shareholding
CStone Pharmaceuticals (HKG:2616) Chief Executive Officer Jianxin Yang purchased an additional 460,000 shares in the open market on June 19 and 20, according to a Monday filing. Yang now has 3,732,500
CStone Pharmaceuticals' Phase 3 Results of Lung Cancer Treatment Trial Published in US Medical Journal
CStone Pharmaceuticals (HKG:2616) said US medical journal Nature Cancer published the results of its overall survival analysis from its phase 3 clinical study assessing sugemalimab for first-line stag
CStone Pharmaceuticals Presents Data From Leukemia Treatment Study During US Oncology Meet
CStone Pharmaceuticals (HKG:2616) presented data from its phase 3 study of its combination of ivosidenib tablets and the chemotherapy azacitidine for newly-diagnosed acute myeloid leukemia at an oncol
CStone Pharmaceuticals CEO Increases Shareholding
CStone Pharmaceuticals (HKG:2616) Chief Executive Officer Jianxin Yang purchased 629,000 shares in the open market for an undisclosed amount, according to a stock exchange filing on Wednesday. The pur
CStone Pharmaceuticals to Regain Commercialization Rights to Cancer Treatments
08:31 PM EDT, 05/08/2023 (MT Newswires) -- CStone Pharmaceuticals (HKG:2616) will regain its development and commercialization rights to cancer treatments sugemalimab and nofazinlimab outside China fo
CStone Pharmaceuticals Enrolls First Patient in China for Phase 1 Trial of Lymphoma Treatment
11:50 PM EDT, 04/23/2023 (MT Newswires) -- CStone Pharmaceuticals (HKG:2616) enrolled the first patient in China for its multi-regional Phase 1 clinical trial of CS5001, a treatment for advanced lymph
Chinese Drug Regulator Accepts CStone Pharmaceuticals' Application for Sugemalimab; Shares Rise 3%
03:23 AM EDT, 04/06/2023 (MT Newswires) -- China's National Medical Products Administration accepted CStone Pharmaceuticals' (HKG:2616) supplemental biologics license application for sugemalimab as a
No Data